Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
“Given that this is in the cancer realm, maybe Pestell attracts the money for the studies - wouldn’t be surprised.”
That’s what I’ve been presuming. Usually I’m too pessimistic to presume something good, but not here.
Form 3, Beneficial ownership. Out today, I think.
So this isn’t Michael Sheikh. More articles trickle in; Good !
Gilead might not be purchasing CYDY. Nobody knows what they’re going to do.
https://endpts.com/an-exodus-of-top-gilead-execs-continues-as-newly-named-cmo-andrew-cheng-heads-for-the-exit/
Thanks, I was going to say something.
No, doctors won’t change their mind until the actually see patients using the “drug”, and that won’t start for 2 years yet. Why don’t doctors care to get new options of treatment for their patients who have limited options ? Or is it just that it’s a questionnaire and they just scribbled some answers. As busy as my niece is, I’d suppose the latter.
So the mono trial won’t finish until a year and a couple months after we get financing. So that means phase 3 ends in Q4 2018 or Q1 2019.
Page 21 of the company’s new investor report says Only 70% of MDs of patients with 3-classes of ART failures would be highly interested in a novel single drug, hiv maintenance therapy. Why isn’t that 100% ? Their patients are running out of options, and they don’t care if there is something new ?
Ok thanks, Axe !
Which probably won’t happen for .... 2-3 months ?
Might Nick be Nader’s son or nephew ?
I was seriously thinking of selling a little more CYDY this week, and moving that into Viking or some more into Galectin .... but now .... how can I? My biggest concern (financing) has been addressed.
Oh yeah, Eddie Murphy ‘Nutty Professor’ ! Except for Shrek, that may have been Murphy’s last funny movie.
Welcome aboard Mr Klump. NOW GET TO WORK !!!! Our conversation last weekend would have been soooooo much different with this bit of news.
Why is CYDY ignored ? 1 OTC, 2 73% Mono and 81% combo efficacy ain’t good enough ? 3 Conspiracy against company and AIDS patients ? 4 Monotherapy will decrease total hiv revenue, so is viewed as a negative 5 BP is stupid ?
None of that makes any sense.
Paulson’s mothers maiden name was Bleucher.
And management who has a clue.
You speak of sense and logic, but I see none in the market for CYDY. I’m beginning to lose trust that there ever will be any sanity on otc. The company’s great promise has been pushed back years as I’ve held on. There are other opportunities elsewhere who appear to have things handled better. They may have less potential return, but I would rather have that for a greater likelihood of return. But I could never sell completely.
That’s right, mono therapy goes out 48 weeks, not 24 weeks.
Wait ! The 525 mg arm has 73% suppression / efficacy at 24 weeks. Doesn’t that meet the primary endpoint ?
I scared everyone away. ??
Are you guys expecting merger news this week .... or just hoping for it ?
We’ve been over this plenty of times before; Pro140 is subcutaneous, lower side effects, more effective ...
Right, I invested in CYDY in part to pay off the mortgage, and my exit has that view in mind. But I’m not selling the instant we hit $3. Depends on the situation.
Yes that too. Some of FDA’s decisions do not make sense.
If there was a buyout offer for $3, we would all vote NO !
I think I might sell enough to pay the mortgage because the fear in the back of my mind is that CYDY will somehow screw it up.
It would pay off the mortgage. I would be sorely tempted. But NOT shares in my IRA.
With CYDY acquisition, might there be a private placement, like TPIV has ? https://finance.yahoo.com/news/tapimmune-announces-pricing-70-million-131500904.htmlhttps://finance.yahoo.com/news/tapimmune-announces-pricing-70-million-131500904.html
Interesting article from 2012 http://blogs.nature.com/tradesecrets/2012/11/16/the-s-3-barometer
No apologies necessary; I wasn’t offended at all. I regularly say much worse while perfectly sober.
Wait ! The 525 mg arm has 73% suppression / efficacy at 24 weeks. Doesn’t that meet the primary endpoint ?
Although cvsi is a drug stock .... it’s a cannabinoid stock. A bit different.
Yes excellent. A more muddled version of that is what led me to reduce my holdings in CYDY. I don’t think anything besides an imminent FDA approval or a big partnership can move the stock. Approval is 18+ months away. I’m looking for companies with shorter-term triggers.
Stinking up the place. Didn’t he get flushed away ?
“Bristol Myers is actively looking for acquisitions in fibrotic diseases.” Back bay is working to sell a company with a trial in liver fibrosis. go Galt !
I almost sold when that aired. I thought, a real company doesn’t do this.
Probably because it’s OTC